Humoral responses to multiple SARS-CoV-2 variants after two doses of vaccine in kidney transplant patients

References

• Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011;11(10):2093–8. doi: 10.1111/j.1600-6143.2011.03686.x
   PubMed Web of Science ®Google Scholar
• Akalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Engl J Med. 2020;382(25):2475–2477. doi: 10.1056/NEJMc2011117
   PubMedGoogle Scholar
• Jager KJ, Kramer A, Chesnaye NC, et al. Results from the ERA-EDTA registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98(6):1540–1548. doi: 10.1016/j.kint.2020.09.006
   PubMed Web of Science ®Google Scholar
• Caillard S, Chavarot N, Francois H, et al. Is COVID-19 infection more severe in kidney transplant recipients? Am J Transplant. 2021;21(3):1295–1303. doi: 10.1111/ajt.16424
   PubMed Web of Science ®Google Scholar
• Babu TM, Kotton CN. Immunizations in chronic kidney disease and kidney transplantation. Curr Treat Options Infect Dis. 2021;13(2):47–65. doi: 10.1007/s40506-021-00248-7
   PubMedGoogle Scholar
• Wang SC, Rai CI, Chen YC. Challenges and recent advancements in COVID-19 vaccines. Microorganisms. 2023;11(3):11. doi: 10.3390/microorganisms11030787
   Web of Science ®Google Scholar
• Rincon-Arevalo H, Choi M, Stefanski AL, et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol. 2021;6(60):6. doi: 10.1126/sciimmunol.abj1031
   Web of Science ®Google Scholar
• Sattler A, Schrezenmeier E, Weber UA, et al. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021;131(14):131. doi: 10.1172/JCI150175
   Web of Science ®Google Scholar
• Caillard S, Thaunat O. COVID-19 vaccination in kidney transplant recipients. Nat Rev Nephrol. 2021;17(12):785–787. doi: 10.1038/s41581-021-00491-7
   PubMed Web of Science ®Google Scholar
• Kuo HC, Kuo KC, Du PX, et al. Profiling humoral immunity after mixing and matching COVID-19 vaccines using SARS-CoV-2 variant protein microarrays. Mol & Cell Proteomics. 2023;22(4):100507. doi: 10.1016/j.mcpro.2023.100507
   PubMed Web of Science ®Google Scholar
• Su WY, Du PX, Santos HM, et al. Antibody profiling in COVID-19 patients with different severities by using spike variant protein microarrays. Anal Chem. 2022;94(17):6529–6539. doi: 10.1021/acs.analchem.1c05567
   PubMed Web of Science ®Google Scholar
• Ho TS, Du PX, Su WY, et al. Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects. Biosens Bioelectron. 2022;204:114067. doi: 10.1016/j.bios.2022.114067
   PubMed Web of Science ®Google Scholar
• Du P-X, Chou Y-Y, Santos HM, et al. Development and application of human coronavirus protein microarray for specificity analysis. Anal Chem. 2021;93(21):7690–7698. doi: 10.1021/acs.analchem.1c00614
   PubMed Web of Science ®Google Scholar
• Du PX, Chou YY, Santos HM, et al. Development and application of human coronavirus protein microarray for specificity analysis. Anal Chem. 2021;93(21):7690. doi: 10.1021/acs.analchem.1c00614
   PubMed Web of Science ®Google Scholar
• Natekar JP, Pathak H, Stone S, et al. Differential pathogenesis of SARS-CoV-2 variants of concern in human ACE2-expressing mice. Viruses. 2022;14(6): 1139. doi: 10.3390/v14061139
   PubMed Web of Science ®Google Scholar
• Alexander J, Liu Z, Eng KY, et al. P75 Vaccine-induced antibody responses against influenza are diminished in infliximab and tofacitinib-treated IBD patients and correlate with responses to COVID-19 vaccination. Gut. 2023;72:A88–A.
   Web of Science ®Google Scholar
• Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(10):1255–1265. doi: 10.1136/annrheumdis-2021-221244
   PubMed Web of Science ®Google Scholar
• Parlakpinar H, Gunata M. Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs. Immunopharmacol Immunotoxicol. 2021;43(6):651–665. doi: 10.1080/08923973.2021.1966033
   PubMed Web of Science ®Google Scholar
• Benotmane I, Gautier-Vargas G, Cognard N, et al. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney Int. 2021;99(6):1498–1500. doi: 10.1016/j.kint.2021.04.005
   PubMed Web of Science ®Google Scholar
• Rozen-Zvi B, Yahav D, Agur T, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect. 2021;27(8):.e1173.1–.e.4. doi: 10.1016/j.cmi.2021.04.028
   Web of Science ®Google Scholar
• Belik M, Liedes O, Vara S, et al. Persistent T cell-mediated immune responses against omicron variants after the third COVID-19 mRNA vaccine dose. Front Immunol. 2023;14:1099246. doi: 10.3389/fimmu.2023.1099246
   PubMed Web of Science ®Google Scholar
• Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186–193. doi: 10.1038/s41590-021-01122-w
   PubMed Web of Science ®Google Scholar
• Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595(7868): 572–577. doi: 10.1038/s41586-021-03653-6
   PubMed Web of Science ®Google Scholar
• Akimoto S, Onoe T, Morimoto H, et al. Analysis of acquisition of COVID-2019 neutralizing antibodies in organ transplant recipients. Transplant Proc. 2023;55(4):815–819. doi: 10.1016/j.transproceed.2023.04.003
   PubMed Web of Science ®Google Scholar
• Bertrand D, Candon S. Protection against SARS-CoV-2 variants with COVID-19 vaccination in kidney transplant recipients. Clin J Am Soc Nephrol. 2022;17(1):3–5. doi: 10.2215/CJN.14881121
   PubMed Web of Science ®Google Scholar
• Chavarot N, Ouedrani A, Marion O, et al. Poor anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept. Transplantation. 2021;105(9):e94–e5. doi: 10.1097/TP.0000000000003784
   PubMed Web of Science ®Google Scholar
• Danthu C, Hantz S, Dahlem A, et al. Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients. J Am Soc Nephrol. 2021;32(9):2153–2158. doi: 10.1681/ASN.2021040490
   PubMed Web of Science ®Google Scholar
• Ou MT, Boyarsky BJ, Chiang TPY, et al. Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking belatacept. Transplantation. 2021;105(9):2119–2123. doi: 10.1097/TP.0000000000003824
   PubMed Web of Science ®Google Scholar
• Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204–2206. doi: 10.1001/jama.2021.7489
   PubMed Web of Science ®Google Scholar
• Reindl-Schwaighofer R, Heinzel A, Mayrdorfer M, et al. Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients: a randomized clinical trial. JAMA Intern Med. 2022;182(2):165–171. doi: 10.1001/jamainternmed.2021.7372
   PubMed Web of Science ®Google Scholar